Follow-up Discussion to the Scientific Presentation by CureVac Representatives to Member State Experts
Nomination by the Joint Negotiation Team and  
7 October 2020
10:00 – 10:30am CET

Subject: CureVac’s mRNA-based vaccine candidate CVnCoV against SARS-CoV2 – Pre-Clinical and available Phase I Data Update provided on 28 September 2020

The Chair opened the meeting and welcomed all participants, including the experts nominated by the Joint Negotiation Team and . A short introduction was provided by the EC as to the purpose of the meeting held on 28 September, where representatives of CureVac provided a data update one month on from the scientific presentation delivered to nominated experts from EU27 and Norway. The EC summarised the discussion around the data update, highlighting that CureVac announced on 28 September that a reanalysis of samples was ongoing. The company explained that the reanalysis of selected samples suggests that a dose higher than may be needed. The final dosage should become clearer by the beginning of . Exploration envisaged to continue in parallel at .

thanked for the opportunity to have a follow-on discussion and highlighted that referred to the reactogenicity profile of the vaccine candidate and specifically the fever events which were moderately alarming – the role of prophylactic paracetamol should be further investigated.

shared concerns raised about the strategy pointed however to additional data on T-cell immunity coming through and the need to await the next review to have a better look at immunogenicity and reactogenicity ratios.
cautioned that the forum should grant more time to CureVac to address the immunogenicity profile in greater depth.

agreed that the next reporting phase should be awaited. The experts should be in a position to examine solid data on neutralising capacity and reactogenicity, as well as driving factors thereof. At the end of more will be known.

stressed the need for more data on risk populations (the elderly, the contingent with comorbidities) and the endpoint of protection against disease.

aligned with earlier speakers and advised to await the next report.

A fair chance should be given for CureVac to address their adverse events.

The Chair thanked all experts for their views and concluded that it is timely to go back to CureVac and request a clearer presentation. The Minutes of the last meeting would also be circulated to the experts for comments and potential remarks. The Chair thanked all for their active engagement and closed the meeting.

Participants

Member States:

(AT)
(DE)
(ES)
(ES)
(FR)
(FR)
(IT)
(IT)
(NL)
(NL)
European Commission:
Sandra Gallina (EC, Chair)